Vaxcyte, Inc. - Common Stock (NQ:PCVX)

71.38 +6.37 (+9.80%)

Delayed Quote Updated: 4:00 PM EDT, Oct 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vaxcyte, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

This Pneumococcal Vaccine Player Is The Top Pick For 2023 For This Analyst ↗

January 03, 2023

Via Benzinga

Tesla To $205? Here Are 10 Other Price Target Changes For Tuesday ↗

January 03, 2023

Goldman Sachs cut Tesla, Inc. (NASDAQ: TSLA) price target from $235 to $205. Goldman Sachs analyst Mark Delaney maintained a Buy rating on the stock. Tesla shares fell 2.6% to $119.93 in pre-market...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For December 16, 2022 ↗

December 16, 2022

Via Benzinga

Why Shares of Vaxcyte Rose 110.7% This Week ↗

October 29, 2022

The company released early data for a promising pneumonia vaccine.

Via The Motley Fool

Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2022 ↗

December 15, 2022

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For November 17, 2022 ↗

November 17, 2022

Upgrades

Via Benzinga

Vaxcyte Reports Third Quarter 2022 Financial Results and Provides Business Update

November 07, 2022

From Vaxcyte, Inc.

Via GlobeNewswire

Vaxcyte to Present at Upcoming Investor Conferences

November 03, 2022

From Vaxcyte, Inc.

Via GlobeNewswire

Why Investors Are Suddenly Excited About Vaxcyte

October 31, 2022

Vaxcyte, Inc. is a small cap biotech company that catapulted back to mid-cap land with a stunning 110% surge — and may not be done yet.

Via MarketBeat

Vaxcyte Announces Closing of $690 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

October 28, 2022

From Vaxcyte, Inc.

Via GlobeNewswire

Wingstop, Harley-Davidson, Rollins And Some Other Big Stocks Moving Higher On Wednesday ↗

October 26, 2022

U.S. stocks traded mixed, with the Dow Jones gaining more than 200 points on Wednesday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Vaxcyte Announces Pricing of $600 Million Public Offering

October 26, 2022

From Vaxcyte, Inc.

Via GlobeNewswire

Avis Budget, Scholastic And Other Big Gainers From Monday ↗

October 25, 2022

U.S. stocks closed higher on Monday, with the Dow Jones gaining over 400 points. Here is the list of some big stocks recording gains in the previous session.

Via Benzinga

Why Tricida Shares Dipped Around 95%; Here Are 73 Biggest Movers From Yesterday ↗

October 25, 2022

Gainers Applied Genetic Technologies Corporation (NASDAQ: AGTC) climbed 62.4% to close at $0.39. Syncona disclosed that it will acquire Applied Genetic Technologies Corporation.

Via Benzinga

Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants

October 24, 2022

From Vaxcyte, Inc.

Via GlobeNewswire

Dow Rises 1.5%; Nasdaq Jumps Over 100 Points ↗

October 24, 2022

U.S. stocks traded higher toward the end of trading, with the Dow Jones surging more than 450 points on Monday.

Via Benzinga

Why Vaxcyte Shares Are Trading Sharply Higher? Here Are 63 Stocks Moving In Monday's Mid-Day Session ↗

October 24, 2022

Gainers Vaxcyte, Inc. (NASDAQ: PCVX) shares jumped 65% to $33.96 after the company announced positive topline results from the Phase 1/2 clinical proof-of-concept study evaluating the safety,...

Via Benzinga

Nasdaq Turns Higher; Applied Genetic Technologies Shares Surge ↗

October 24, 2022

U.S. stocks traded mostly higher midway through trading, with the Dow Jones surging more than 300 points on Monday.

Via Benzinga

Vaxcyte Shares Surge As Its Pneumococcal Vaccine On Par With Pfizer's Shot In Study ↗

October 24, 2022

Via Benzinga

Why Is Tricida (TCDA) Stock Down 90% Today? ↗

October 24, 2022

Tricida (TCDA) stock is falling on Monday following the release of poor results from a Phase 3 chronic kidney disease clinical trial.

Via InvestorPlace

How Is The Market Feeling About Vaxcyte? ↗

October 24, 2022

Vaxcyte's (NASDAQ:PCVX) short percent of float has risen 22.85% since its last report. The company recently reported that it has 2.48 million shares sold short, which is 5.43% of all regular shares...

Via Benzinga

Why Is Vaxcyte (PCVX) Stock Up 70% Today? ↗

October 24, 2022

Vaxcyte (PCVX) stock is rocketing higher on Monday after the vaccine company revealed positive data from a Phase 1/2 clinical trial.

Via InvestorPlace

US Stocks Mixed; Dow Jumps 200 Points ↗

October 24, 2022

U.S. stocks traded mixed this morning, with the Dow Jones surging around 200 points on Monday.

Via Benzinga

Vaxcyte Shares Are Soaring: Here's Why ↗

October 24, 2022

Vaxcyte Inc (NASDAQ: PCVX) shares are trading higher Monday after the company announced positive topline results from the Phase 1/2 clinical proof-of-concept study evaluating the safety, tolerability...

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

October 24, 2022

Gainers Applied Genetic Techs (NASDAQ:AGTC) shares moved upwards by 62.0% to $0.39 during Monday's pre-market session. The company's market cap stands at $26.3 million.

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗

October 24, 2022

Good morning, traders! We're starting off the week with a breakdown of the biggest pre-market stock movers for Monday morning!

Via InvestorPlace

Vaxcyte Reports Positive Topline Data from Phase 1/2 Proof-of-Concept Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults Aged 18-64

October 24, 2022

From Vaxcyte, Inc.

Via GlobeNewswire

Vaxcyte to Host Webcast and Conference Call to Discuss Topline Results from the Phase 1/2 Proof-of-Concept Study of VAX-24 Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults

October 23, 2022

From Vaxcyte, Inc.

Via GlobeNewswire

Vaxcyte Expands Executive Leadership Team with Key Appointments

October 11, 2022

From Vaxcyte, Inc.

Via GlobeNewswire

Vaxcyte Completes Enrolment In Mid-Stage Pneumococcal Disease Study, Sees Top-line Data In H1 2013 ↗

September 06, 2022

Vaxcyte (NASDAQ: PCVX) has completed patient enrollment in the Phase 2 study evaluating VAX-24 in healthy adults 65 years of age and older. VAX-24 is its lead, 24-valent pneumococcal conjugate vaccine...

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.